Sunitinib
CAS 557795-19-4
Sunitinib (CAS 557795-19-4) is a pharmaceutical compound with 80 bioactivity targets and 498 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
283
SOURCE
DrugCentral
Adverse signals
498
SOURCE
IUPHAR/BPS
PubMed IDs
25
SOURCE
DrugCentral
055904D152D6
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Sunitinib
CAS Number
557795-19-4
UNII
V99T50803M
InChIKey
WINHZLLDWRZWRT-ATVHPVEESA-N
ChEMBL ID
CHEMBL1567
DrugCentral Struct ID
2544
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
Synonyms and normalized names
SUNITINIB MALATESutent
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Focal adhesion kinase 1 Kinase |
Kd | 6.36 | - | Homo sapiens |
| Tyrosine-protein kinase HCK Kinase |
Kd | 6.06 | - | Homo sapiens |
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 5.92 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily H member 2 Ion channel |
IC50 | 6.3 | - | Homo sapiens |
| ATP-binding cassette sub-family G member 2 Transporter |
IC50 | 5.52 | - | Homo sapiens |
| Acetylcholinesterase Enzyme |
IC50 | 5.23 | - | Homo sapiens |
| Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme |
Kd | 5.4 | - | Homo sapiens |
| Platelet-derived growth factor receptor beta Kinase |
Kd | 10.12 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 7.26 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 9.68 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
Kd | 6.07 | - | Homo sapiens |
| Pyridoxal kinase Kinase |
Kd | 5.22 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
Kd | 5.68 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 6.64 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Kd | 6.92 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 6.28 | - | Homo sapiens |
| Receptor-type tyrosine-protein kinase FLT3 Kinase |
Kd | 9.66 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 2 Kinase |
Kd | 9.7 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 3 Kinase |
Ki | 7.77 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
Kd | 8.7 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-3 Kinase |
Kd | 7.26 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase |
Kd | 8.23 | - | Homo sapiens |
| Insulin-like growth factor 1 receptor Kinase |
Kd | 5.59 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
Kd | 7.64 | - | Homo sapiens |
| Insulin receptor Kinase |
Kd | 6.74 | - | Homo sapiens |
| Death-associated protein kinase 3 Kinase |
Kd | 7.66 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1 Kinase |
Kd | 6.01 | - | Homo sapiens |
| Fibroblast growth factor receptor 3 Kinase |
Kd | 6.54 | - | Homo sapiens |
| Rho-associated protein kinase 1 Kinase |
Kd | 6.34 | - | Homo sapiens |
| Tyrosine-protein kinase JAK1 Kinase |
Kd | 8.05 | - | Homo sapiens |
| Mitogen-activated protein kinase 10 Kinase |
Kd | 5.37 | - | Homo sapiens |
| Death-associated protein kinase 2 Kinase |
Kd | 6.82 | - | Homo sapiens |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase |
IC50 | 4.92 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 7 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 6.39 | - | Homo sapiens |
| Rho-associated protein kinase 2 Kinase |
Kd | 6.85 | - | Homo sapiens |
| Protein kinase C alpha type Kinase |
Kd | 5.22 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase |
Kd | 6.38 | - | Homo sapiens |
| Myosin light chain kinase 2, skeletal/cardiac muscle Kinase |
Kd | 7.31 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase |
Kd | 6.36 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 7.96 | - | Homo sapiens |
| Serine/threonine-protein kinase MARK2 Kinase |
Kd | 6.51 | - | Homo sapiens |
| Hepatocyte growth factor receptor Kinase |
Kd | 5.92 | - | Homo sapiens |
| Tyrosine-protein kinase Lyn Kinase |
Kd | 6.57 | - | Homo sapiens |
| Serine/threonine-protein kinase Nek2 Kinase |
Kd | 6.3 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-2 Kinase |
Kd | 7.77 | - | Homo sapiens |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase |
Kd | 7.72 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase |
Kd | 5.85 | - | Homo sapiens |
| Fibroblast growth factor receptor 1 Kinase |
Kd | 6.28 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase |
Kd | 8.26 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Disease progression | 2387 | 3715.106 | 10061818 |
| Neoplasm progression | 1097 | 2358.96 | 10061309 |
| Palmar-plantar erythrodysaesthesia syndrome | 986 | 2354.256 | 10033553 |
| Death | 2753 | 1859.277 | 10011906 |
| Dysgeusia | 705 | 1101.274 | 10013911 |
| Yellow skin | 272 | 895.114 | 10048245 |
| Diarrhoea | 2387 | 831.254 | 10012735 |
| Hypothyroidism | 550 | 792.318 | 10021114 |
| Oral pain | 449 | 771.421 | 10031009 |
| Stomatitis | 807 | 677.445 | 10042128 |
| Hair colour changes | 222 | 665.187 | 10019030 |
| Decreased appetite | 1139 | 566.828 | 10061428 |
| Drug ineffective | 292 | 564.086 | 10013709 |
| Thrombocytopenia | 970 | 552.286 | 10043554 |
| Hypertension | 1135 | 550.423 | 10020772 |
| Platelet count decreased | 790 | 519.658 | 10035528 |
| Osteonecrosis of jaw | 389 | 513.744 | 10064658 |
| Fatigue | 2162 | 451.019 | 10016256 |
| Ageusia | 255 | 418.599 | 10001480 |
| Mucosal inflammation | 409 | 357.342 | 10028116 |
| Asthenia | 1199 | 333.929 | 10003549 |
| Dry skin | 344 | 269.384 | 10013786 |
| Second primary malignancy | 165 | 241.492 | 10039801 |
| Rheumatoid arthritis | 3 | 240.117 | 10039073 |
| Off label use | 410 | 234.048 | 10053762 |
| Bone marrow failure | 263 | 222.386 | 10065553 |
| Epistaxis | 386 | 216.152 | 10015090 |
| Pleural effusion | 442 | 205.859 | 10035598 |
| Blood pressure increased | 595 | 205.284 | 10005750 |
| Skin discolouration | 233 | 196.302 | 10040829 |
| Dehydration | 609 | 194.79 | 10012174 |
| Dyspepsia | 377 | 184.042 | 10013946 |
| Malignant neoplasm progression | 419 | 181.525 | 10051398 |
| Nausea | 1639 | 180.678 | 10028813 |
| Therapeutic product effect decreased | 4 | 180.581 | 10082201 |
| Drug hypersensitivity | 57 | 177.723 | 10013700 |
| Arthropathy | 15 | 175.658 | 10003285 |
| Blood thyroid stimulating hormone increased | 112 | 172.897 | 10005833 |
| Completed suicide | 7 | 167.823 | 10010144 |
| Skin exfoliation | 240 | 164.357 | 10040844 |
| Renal cell carcinoma | 96 | 160.385 | 10067946 |
| Oral discomfort | 105 | 151.8 | 10030973 |
| Hypersensitivity | 66 | 139.878 | 10020751 |
| Vomiting | 1145 | 139.062 | 10047700 |
| Intentional product use issue | 14 | 138.691 | 10076308 |
| Hyperkeratosis | 92 | 137.787 | 10020649 |
| Sinusitis | 31 | 131.708 | 10040753 |
| Joint swelling | 89 | 127.83 | 10023232 |
| Arthralgia | 278 | 127.292 | 10003239 |
| Treatment failure | 34 | 124.176 | 10066901 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
11 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| KIT proto-oncogene, receptor tyrosine kinase KIT |
Inhibition | 7.880000114440918 pIC50 | 20570526 |
| KIT proto-oncogene, receptor tyrosine kinase KIT |
Inhibition | 9.430000305175781 pKd | 22037378 |
| fms related receptor tyrosine kinase 4 FLT4 |
Inhibition | 8.050000190734863 pIC50 | 20570526 |
| platelet derived growth factor receptor beta PDGFRB |
Inhibition | 8.100000381469727 pKi | 12538485 |
| platelet derived growth factor receptor beta PDGFRB |
Inhibition | 8.199999809265137 pIC50 | 23279183 |
| fibroblast growth factor receptor 1 FGFR1 |
Inhibition | 6.079999923706055 pKi | 12538485 |
| fms related receptor tyrosine kinase 3 FLT3 |
Inhibition | 8.1899995803833 pIC50 | 20570526 |
| kinase insert domain receptor KDR |
Inhibition | 7.650000095367432 pIC50 | 20570526 |
| large tumor suppressor kinase 1 LATS1 |
Inhibition | 6.199999809265137 pKd | - |
| large tumor suppressor kinase 2 LATS2 |
Inhibition | 6.340000152587891 pKd | 19654408 |
| ret proto-oncogene RET |
Inhibition | 8.800000190734863 pIC50 | 23279183 |
SOURCE
PharmGKB
60 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
FLT3 (PA28181) rs1933437
Genotypes AG + GG is associated with decreased likelihood of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype AA.
Evidence: -; PMID 20683446
CXCL8 (PA29841) rs1126647
Allele T is associated with decreased overall survival when treated with pazopanib or sunitinib in people with Carcinoma, Renal Cell as compared to allele A.
Evidence: -; PMID 25695485
NR1I3 (PA391) rs2307424
Genotypes AA + AG is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.
Evidence: -; PMID 23462807
ABCB1 (PA267) rs2032582
Genotypes AA + AT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.
Evidence: -; PMID 24874929
KDR (PA30086) rs34231037
Genotype AG is associated with increased clinical benefit to sunitinib as compared to genotype GG.
Evidence: -; PMID 28430711
CYP3A5 (PA131) rs776746
Genotype TT is associated with increased risk of dose reductions due to toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele C.
Evidence: -; PMID 22015057
FLT4 (PA28183) rs307821
Genotype AC is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.
Evidence: -; PMID 22015057
FLT4 (PA28183) rs307826
Genotype CT is associated with reduced progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT.
Evidence: -; PMID 22015057
FLT1 (PA28180) rs9582036
Genotype CC is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AC.
Evidence: -; PMID 26935927
FLT1 (PA28180) rs9554320
Genotype AA is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.
Evidence: -; PMID 23421954
SLC22A5 (PA333) rs2631370
Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele T.
Evidence: -; PMID 28117434
ABCB1 (PA267) rs1045642
Genotypes AA + AG is associated with increased clearance of sunitinib in people with Carcinoma, Renal Cell and Neoplasm Metastasis as compared to genotype GG.
Evidence: -; PMID 27485537
FLT4 (PA28183) rs307821
Genotypes AA + AC is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.
Evidence: -; PMID 23462807
VEGFA (PA37302) rs833061
Allele C is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele T.
Evidence: -; PMID 22948895
VEGFA (PA37302) rs699947
Allele A is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele C.
Evidence: -; PMID 22948895
VEGFA (PA37302) rs2010963
Allele G is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele C.
Evidence: -; PMID 22948895
NOS3 (PA254) rs2070744
Genotypes CC + CT are associated with increased risk of grade 3 hypertension when treated with sunitinib as compared to genotype TT.
Evidence: -; PMID 22948895
ABCB1 (PA267) rs1045642
Genotype GG is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.
Evidence: -; PMID 25778465
ABCB1 (PA267) rs1045642
Genotype GG is associated with increased exposure to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.
Evidence: -; PMID 25778465
KDR (PA30086) rs1870377
Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele T.
Evidence: -; PMID 24013576
PDGFRA (PA33147) rs35597368
Genotypes CC + CT is not associated with overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT.
Evidence: -; PMID 24013576
ABCG2 (PA390) rs2231142
Genotype TT is associated with increased risk of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.
Evidence: -; PMID 24013576
ABCG2 (PA390) rs2231142
Genotype TT is associated with increased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.
Evidence: -; PMID 24013576
KDR (PA30086) rs2305948
Allele C is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele T.
Evidence: -; PMID 24013576
CYP3A5 (PA131) rs776746
Allele C is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele T.
Evidence: -; PMID 24013576
RET (PA34335) rs1799939
Genotypes AA + AG is not associated with overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.
Evidence: -; PMID 24013576
FLT3 (PA28181) rs1933437
Allele A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.
Evidence: -; PMID 24013576
CYP1A1 (PA27092) rs1048943
Genotype A is not associated with Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype G.
Evidence: -; PMID 24013576
ABCB1 (PA267) rs2032582
Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.
Evidence: -; PMID 26244574
FLT3 (PA28181) rs1933437
Genotype AA is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.
Evidence: -; PMID 26244574
SOURCE
NLM RxNorm
7 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| SUNITINIB | 357977 | SU | MTHSPL |
| SUNITINIB MALATE | 616275 | SU | MTHSPL |
| sunitinib | 357977 | IN | RXNORM |
| SUNItinib | 357977 | TMSY | RXNORM |
| Sutent | 616274 | BN | RXNORM |
| sunitinib malate | 616275 | PIN | RXNORM |
| SUNItinib malate | 616275 | TMSY | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal abscess | sunitinib | LLT | C0243001 |
| Abdominal abscess | sunitinib | PT | C0243001 |
| Abdominal discomfort | sunitinib | LLT | C0232487 |
| Abdominal discomfort | sunitinib | PT | C0232487 |
| Abdominal distension | sunitinib | LLT | C0000731 |
| Abdominal distension | sunitinib | PT | C0000731 |
| Abdominal pain | sunitinib | LLT | C0000737 |
| Abdominal pain | sunitinib | PT | C0000737 |
| Abdominal pain upper | sunitinib | LLT | C0232492 |
| Abdominal pain upper | sunitinib | PT | C0232492 |
| Abdominal sepsis | sunitinib | LLT | C1141926 |
| Abdominal sepsis | sunitinib | PT | C1141926 |
| Abscess | sunitinib | LLT | C0000833 |
| Abscess | sunitinib | PT | C0000833 |
| Abscess limb | sunitinib | LLT | C0578455 |
| Abscess limb | sunitinib | PT | C0578455 |
| Acalculous cholecystitis | sunitinib | LLT | C0267841 |
| Acne | sunitinib | LLT | C0702166 |
| Acne | sunitinib | PT | C0702166 |
| Acute coronary syndrome | sunitinib | LLT | C0948089 |
| Acute coronary syndrome | sunitinib | PT | C0948089 |
| Adrenal insufficiency | sunitinib | LLT | C0001623 |
| Adrenal insufficiency | sunitinib | PT | C0001623 |
| Ageusia | sunitinib | LLT | C2364111 |
| Ageusia | sunitinib | PT | C2364111 |
| Alanine aminotransferase increased | sunitinib | LLT | C0151905 |
| Alanine aminotransferase increased | sunitinib | PT | C0151905 |
| Albumin low | sunitinib | LLT | C0860864 |
| Alertness decreased | sunitinib | LLT | C0877609 |
| Alopecia | sunitinib | LLT | C0002170 |
| Alopecia | sunitinib | PT | C0002170 |
| Amylase increased | sunitinib | LLT | C0151479 |
| Amylase increased | sunitinib | PT | C0151479 |
| Anaemia | sunitinib | LLT | C0002871 |
| Anaemia | sunitinib | PT | C0002871 |
| Anal abscess | sunitinib | LLT | C0281778 |
| Anal abscess | sunitinib | PT | C0281778 |
| Anal fistula | sunitinib | LLT | C0205929 |
| Anal fistula | sunitinib | PT | C0205929 |
| Angioedema | sunitinib | LLT | C0002994 |
| Angioedema | sunitinib | PT | C0002994 |
| Angiopathy | sunitinib | LLT | C0042373 |
| Angiopathy | sunitinib | PT | C0042373 |
| Anorexia | sunitinib | LLT | C0003123 |
| Aphthous stomatitis | sunitinib | LLT | C0038363 |
| Aphthous stomatitis | sunitinib | PT | C0038363 |
| Apoptosis | sunitinib | LLT | C0162638 |
| Apoptosis | sunitinib | PT | C0162638 |
| Arrhythmia | sunitinib | LLT | C0003811 |
| Arrhythmia | sunitinib | PT | C0003811 |
| Arthralgia | sunitinib | LLT | C0003862 |
| Arthralgia | sunitinib | PT | C0003862 |
| Aspartate aminotransferase increased | sunitinib | LLT | C0151904 |
| Aspartate aminotransferase increased | sunitinib | PT | C0151904 |
| Asthenia | sunitinib | LLT | C0004093 |
| Asthenia | sunitinib | PT | C0004093 |
| Asthenia | sunitinib | PT | C0004093 |
| Back pain | sunitinib | LLT | C0004604 |
| Back pain | sunitinib | PT | C0004604 |
| Bacterial infection | sunitinib | LLT | C0004623 |
| Bacterial infection | sunitinib | PT | C0004623 |
| Bilirubin total increased | sunitinib | LLT | C0741494 |
| Blindness | sunitinib | PT | C0456909 |
| Blindness cortical | sunitinib | LLT | C0155320 |
| Blindness cortical | sunitinib | PT | C0155320 |
| Blister | sunitinib | LLT | C0005758 |
| Blister | sunitinib | PT | C0005758 |
| Blood albumin decreased | sunitinib | PT | C0853777 |
| Blood alkaline phosphatase increased | sunitinib | PT | C0852911 |
| Blood and lymphatic system disorders | sunitinib | - | C0851353 |
| Blood bilirubin increased | sunitinib | LLT | C0311468 |
| Blood bilirubin increased | sunitinib | PT | C0311468 |
| Blood bilirubin increased | sunitinib | PT | C0311468 |
| Blood calcium decreased | sunitinib | PT | C3665624 |
| Blood creatinine increased | sunitinib | PT | C0235431 |
| Blood creatinine increased | sunitinib | LLT | C0235431 |
| Blood creatinine increased | sunitinib | PT | C0235431 |
| Blood disorder | sunitinib | LLT | C0018939 |
| Blood disorder | sunitinib | PT | C0018939 |
| Blood glucose decreased | sunitinib | PT | C0595883 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sunitinib used for in pharmaceutical contexts?
Sunitinib (CAS 557795-19-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sunitinib?
Sunitinib has 498 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Disease progression, Neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, Death, Dysgeusia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sunitinib also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Sunitinib.
What clinical phase is Sunitinib in?
No phase 1-4 clinical development badge is rendered for Sunitinib because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Sunitinib?
Sunitinib has 283 bioactivity rows in this page query. Rendered target entries include Focal adhesion kinase 1, Tyrosine-protein kinase HCK, Tyrosine-protein kinase JAK3, Potassium voltage-gated channel subfamily H member 2, ATP-binding cassette sub-family G member 2.